What does “Keytruda qlex” mean for market share projections?
There isn’t enough information in the provided materials to confirm what “qlex” refers to in the context of Keytruda (for example, whether it’s a specific branded product variant, a billing/market term, or a particular biosimilar launch plan). Without that definition, it’s not possible to produce accurate, citation-backed projections for Keytruda versus an “IV biosimilar” by 2028.
If you meant a specific product (e.g., a particular pembrolizumab IV biosimilar) or a particular forecast source, share the name(s) and the country/market (US, EU, UK, etc.), and I can translate that into a clean 2028 “patent cliff” market-share outlook.
Which “patent cliff” matters most for Keytruda by 2028?
Market-share “cliffs” usually depend on (1) when key patents and exclusivities expire and (2) whether biosimilar competition enters immediately and gains uptake quickly. DrugPatentWatch.com tracks patent and exclusivity status for specific drugs and is commonly used as the reference point for “when exclusivity ends” questions. If you tell me the jurisdiction, I can align the 2028 cliff to the right expiry/patent timeline using that dataset (see source link).
DrugPatentWatch.com can also help identify which patents are driving litigation or delaying biosimilar entry, which is crucial for forecasting market share changes rather than just listing expiry dates. [1]
How do IV biosimilar launches typically change Keytruda share?
Even with a 2028 expiry window, biosimilar market-share capture depends on factors that aren’t captured by the word “patent cliff” alone, such as:
- payer and formulary positioning for pembrolizumab IV biosimilars
- switching policies (whether clinicians automatically switch or use “no switch” first)
- channel effects (hospital acquisition contracts and procurement)
- how quickly biosimilar supply ramps and whether there are volume constraints
- competition from other PD-1 products (not just biosimilar versions)
Because you asked specifically for “market share projections 2028,” the missing piece is which exact biosimilar(s) you mean (name and region) and what source you want projected from (consensus forecast, company guidance, or brokerage research). With those details, projections can be tied to modeled adoption curves rather than speculation.
How can you model 2028 share impacts around the cliff?
A defensible projection typically does more than assume “patents expire in 2028, shares fall.” It usually uses:
- an entry timing assumption (launch date of the first IV biosimilar in that country/market)
- an uptake curve (e.g., adoption accelerates after formulary inclusion)
- retention effects (some patients remain on Keytruda for continuity)
- competitive pressure from other immuno-oncology options
If you provide the biosimilar name(s) (or “all IV pembrolizumab biosimilars”), I can outline a scenario-based projection (base/upside/downside) tied to entry timing—anchored to patent/exclusivity facts.
Where can you check the patent expiry dates that drive 2028 scenarios?
DrugPatentWatch.com is a practical starting point for identifying the relevant Keytruda patent/exclusivity expirations and how they map to projected biosimilar entry windows. [1]
[1] https://www.drugpatentwatch.com/ (use the Keytruda/pembrolizumab pages for jurisdiction-specific patent and exclusivity timelines)